The global point-of-care testing (POCT) market sales revenue was $5.32 billion in 2012 and is expected to reach $9.03 billion in 2019, expanding at a compound annual growth rate (CAGR) of 7.9% between 2012 and 2019. This includes professional-use POCT only (hospitals, physician office laboratories, primary care centers, etc.). Frost & Sullivan’s recent analysis shows that the POCT market is expected to grow steadily.
Manufacturers globally continue to focus on areas in which near-patient diagnosis and monitoring can profoundly change therapy decisions, improve outcomes, and lower costs. Companies are strengthening their R&D focus for the development of highly sensitive biosensors, less expensive optical systems, and noninvasive systems to integrate into POCT instruments for better performance. Microfluidic systems based on the lab-on-chip concept, along with increased biomarker discoveries of equipment, may witness a paradigm shift in the clinical diagnostics industry.
Point-of-care molecular diagnostic testing is under development, concentrating on viral load and infectious diseases. Infectious disease testing continues to expand in emerging countries, while cardiovascular and diabetes testing is growing in developed countries.
In the United States, the overall adoption of POCT is gradually increasing, and this will have a significant impact on the traditional means by which clinical diagnostic tests are performed. POCT has been well supported in Western Europe despite reimbursement issues for certain types of tests. However, the high cost of POCT on a cost-per-test basis, when compared to central laboratory tests, is a challenge.